New study adds to confused picture on AstraZeneca's influenza vaccine FluMist

19 August 2016

Anglo-Swedish pharma major AstraZeneca’s FluMist Quadrivalent nasal vaccine offers the same protection as an injectable vaccine, according to a study appearing in the Annals of Internal Medicine.

This has been published just two months after updated guidance from the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) advised against using AstraZeneca’s product in any setting.

The Annals of Internal Medicine study analyzed whether this intranasal live attenuated influenza vaccine (LAIV) was more effective than inactivated influenza vaccine (IIV) 52 Hutterite colonies in Alberta and Saskatchewan, Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK